Cargando…

A Brief Review of Natural Products with Urate Transporter 1 Inhibition for the Treatment of Hyperuricemia

Hyperuricemia is a common disease caused by a high level of uric acid. Urate transporter 1 (URAT1) is an important protein and mediates approximately 90% of uric acid reabsorption. Therefore, the URAT1 inhibitor is a class of uricosuric medicines widely used in the clinic for the treatment of hyperu...

Descripción completa

Detalles Bibliográficos
Autores principales:	Yuan, Qianghua, Cheng, Yuan, Sheng, Rong, Yuan, Yan, Hu, Mei
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Hindawi 2022
Materias:	Review Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9635963/ https://www.ncbi.nlm.nih.gov/pubmed/36337587 http://dx.doi.org/10.1155/2022/5419890

Ejemplares similares

Variation of Urate Transport in the Nephrons in Subtypes of Hyperuricemia
por: Nakamura, Toru, et al.
Publicado: (2013)

The impact of an URAT1 polymorphism on the losartan treatment of hypertension and hyperuricemia
por: Wu, Liting, et al.
Publicado: (2021)

Physiology of Hyperuricemia and Urate-Lowering Treatments
por: Benn, Caroline L., et al.
Publicado: (2018)

Quantitative Estimation of Urate Transport in Nephrons in Relation to Urinary Excretion Employing Benzbromarone-Loading Urate Clearance Tests in Cases of Hyperuricemia
por: Nakamura, Toru, et al.
Publicado: (2011)

Identification of GLUT12/SLC2A12 as a urate transporter that regulates the blood urate level in hyperuricemia model mice
por: Toyoda, Yu, et al.
Publicado: (2020)

An evidence-based review on urate-lowering treatments: implications for optimal treatment of chronic hyperuricemia
por: Bove, Marilisa, et al.
Publicado: (2017)

ABCG2 dysfunction causes hyperuricemia due to both renal urate underexcretion and renal urate overload
por: Matsuo, Hirotaka, et al.
Publicado: (2014)

The urate-lowering efficacy and safety of febuxostat in the treatment of the hyperuricemia of gout: the CONFIRMS trial
por: Becker, Michael A, et al.
Publicado: (2010)

Bergenin as a Novel Urate-Lowering Therapeutic Strategy for Hyperuricemia
por: Chen, Mo, et al.
Publicado: (2020)

Urate‐induced immune programming: Consequences for gouty arthritis and hyperuricemia
por: Cabău, Georgiana, et al.
Publicado: (2019)

Mechanism of high affinity inhibition of the human urate transporter URAT1
por: Tan, Philip K., et al.
Publicado: (2016)

Decreased extra-renal urate excretion is a common cause of hyperuricemia
por: Ichida, Kimiyoshi, et al.
Publicado: (2012)

Discovery and characterization of verinurad, a potent and specific inhibitor of URAT1 for the treatment of hyperuricemia and gout
por: Tan, Philip K., et al.
Publicado: (2017)

Engineered Escherichia coli Nissle 1917 with urate oxidase and an oxygen-recycling system for hyperuricemia treatment
por: Zhao, Rui, et al.
Publicado: (2022)

Alterations in lipidome profiles distinguish early-onset hyperuricemia, gout, and the effect of urate-lowering treatment
por: Kvasnička, Aleš, et al.
Publicado: (2023)

Hyperuricemia, urate-lowering therapy, and kidney outcomes: a systematic review and meta-analysis
por: Sharma, Gaurav, et al.
Publicado: (2021)

Familial early-onset hyperuricemia and gout associated with a newly identified dysfunctional variant in urate transporter ABCG2
por: Toyoda, Yu, et al.
Publicado: (2019)

Common UCP2 variants contribute to serum urate concentrations and the risk of hyperuricemia
por: Yang, Luyu, et al.
Publicado: (2016)

Catalysis and Structure of Zebrafish Urate Oxidase Provide Insights into the Origin of Hyperuricemia in Hominoids
por: Marchetti, Marialaura, et al.
Publicado: (2016)

Hyperuricemia in acute gastroenteritis is caused by decreased urate excretion via ABCG2
por: Matsuo, Hirotaka, et al.
Publicado: (2016)

Urate transport capacity of glucose transporter 9 and urate transporter 1 in cartilage chondrocytes
por: Zhang, Bingqing, et al.
Publicado: (2019)

Hypouricemia and Urate Transporters
por: Otani, Naoyuki, et al.
Publicado: (2022)

Comparative efficacy and safety of urate-lowering therapy for the treatment of hyperuricemia: a systematic review and network meta-analysis
por: Li, Shu, et al.
Publicado: (2016)

Identification of Two Dysfunctional Variants in the ABCG2 Urate Transporter Associated with Pediatric-Onset of Familial Hyperuricemia and Early-Onset Gout
por: Toyoda, Yu, et al.
Publicado: (2021)

Pitfalls, prevention, and treatment of hyperuricemia during tumor lysis syndrome in the era of rasburicase (recombinant urate oxidase)
por: Pession, Andrea, et al.
Publicado: (2008)

Oral Treatment With an Engineered Uricase, ALLN-346, Reduces Hyperuricemia, and Uricosuria in Urate Oxidase-Deficient Mice
por: Pierzynowska, Kateryna, et al.
Publicado: (2020)

Anti-Inflammatory and Anti-Hyperuricemic Effects of Chrysin on a High Fructose Corn Syrup-Induced Hyperuricemia Rat Model via the Amelioration of Urate Transporters and Inhibition of NLRP3 Inflammasome Signaling Pathway
por: Chang, Yi-Hsien, et al.
Publicado: (2021)

Urate-Lowering Therapy Ameliorates Kidney Function in Type 2 Diabetes Patients With Hyperuricemia
por: Ueno, Naohiko
Publicado: (2017)

Molecular Elucidation of a Urate Oxidase from Deinococcus radiodurans for Hyperuricemia and Gout Therapy
por: Chiu, Yi-Chih, et al.
Publicado: (2021)

Eggshell Membrane Ameliorates Hyperuricemia by Increasing Urate Excretion in Potassium Oxonate-Injected Rats
por: Sung, Yoon-Young, et al.
Publicado: (2021)

Effect of Urate-Lowering Therapy on the Progression of Kidney Function in Patients With Asymptomatic Hyperuricemia: A Systematic Review and Meta-Analysis
por: Zhang, Lin, et al.
Publicado: (2022)

Genetic polymorphisms and decreased protein expression of ABCG2 urate transporters are associated with susceptibility to gout, disease severity and renal-overload hyperuricemia
por: Pálinkás, Márton, et al.
Publicado: (2022)

Modulation of Urate Transport by Drugs
por: Tátrai, Péter, et al.
Publicado: (2021)

Identification of monosodium urate crystal deposits in patients with asymptomatic hyperuricemia using dual-energy CT
por: Wang, Penny, et al.
Publicado: (2018)

Dotinurad: a novel selective urate reabsorption inhibitor as a future therapeutic option for hyperuricemia
por: Kuriyama, Satoru
Publicado: (2019)

The Effective Control of Hyperuricemia in Cancer Patients: A New Recombinant Conjugated Variant of Urate Oxidase
por: Najjari, Abbas, et al.
Publicado: (2021)

Ependymal cells of the mouse brain express urate transporter 1 (URAT1)
por: Tomioka, Naoko H, et al.
Publicado: (2013)

Hyperuricemia and Progression of Chronic Kidney Disease: A Review from Physiology and Pathogenesis to the Role of Urate-Lowering Therapy
por: Lee, Tao Han, et al.
Publicado: (2021)

Natural antibodies and CRP drive anaphylatoxin production by urate crystals
por: Wessig, Anne Kathrin, et al.
Publicado: (2022)

Loss of the Kidney Urate Transporter, Urat1, Leads to Disrupted Redox Homeostasis in Mice
por: Jamshidi, Neema, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_bjtpb4en31m6t5bbu3n3abeape